Egetis Appoints Tiago Nunes as Chief Medical Officer

April 9, 2026 1:15 AM

Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Officer (CMO), effective May 1, 2026. Tiago Nunes is an experienced clinical development leader, with significant expertise advancing rare disease therapeutics through regulatory approval and launch, having most recently served as Senior Vice President, Clinical Development at Mirum Pharmaceuticals...

Read more

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

April 8, 2026 12:45 PM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA clinical trial evaluating IGC-AD1 for Alzheimer's-related agitation today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.25 per share.The research report entitled, "Reports Q3. We believe more positive...

Read more

NGD Infection Prevention Introduces Novel Means to Reduce Length-of-Stay at Becker's Healthcare Conference

April 8, 2026 10:00 AM

Next Gen Diagnostics (NGD) will showcase its new NGD System at Becker's Healthcare Conference, in Chicago, April 13-16. Attendees can visit Booth #115 to see how NGD's end-to-end, on-premise service enables hospitals to detect and stop infection transmission in real time.The NGD System integrates complete robotic sample preparation, sequencing, bioinformatics and detection of the transmission of bacterial infection, all in an efficient, low-cost...

Read more

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

April 7, 2026 8:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's disease, today announced the activation of a new clinical trial site at Tandem Clinical Research A Prolerity Network Site in Metairie, Louisiana, for the Company's ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation in Alzheimer's dementia. The site, located at 3901 Houma...

Read more

Moolec Science Announces Breakthrough in Molecular Farming With Successful Expression of Bovine Myoglobin in Pea Seeds

April 7, 2026 8:00 AM

Moolec Science Limited, a wholly owned subsidiary of Moolec Science SA (NASDAQ:MLEC) ("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced a significant scientific breakthrough in the production of animal proteins in plants.Through a sponsored research project with one of the most prestigious academic institutions in the United...

Read more

Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million

April 7, 2026 7:00 AM

Precigen Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company developing precision medicines to improve the quality of life for people suffering from recurrent respiratory papillomatosis (RRP) and other diseases, is making progress on that front, announcing it has seen "robust uptake" in usage of PAPZIMEOS (zopapogene imadenovec-drba), since launching the immunotherapy in August 2025. What's more, the company announced that the...

Read more

Theis Kipling New CEO for Biovica

April 7, 2026 3:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The Biovica board has appointed Theis Kipling as the new Chief Executive Officer. He will assume the position no later than September 2026.Theis Kipling brings extensive international experience from leading global commercial organizations in the life sciences and diagnostics sectors. He has a strong track record of driving global sales growth and building successful commercial...

Read more

Bora Biologics Successfully Completes 2,000L Engineering and Scale-Up Run in San Diego, Reinforcing Commercial-Scale Readiness

April 6, 2026 7:50 AM

Bora Biologics today announced the successful completion of its first 2,000-liter engineering, scale up, and process confirmation run at its FDA-approved San Diego facility, marking a key milestone following the company's recent $30 million expansion. The engineering run confirms operational readiness of the expanded mammalian manufacturing suites and validates the facility's integrated upstream, downstream, and quality systems at...

Read more

Cambridge Isotope Laboratories Announces Eurisotop as Direct Supplier of Environmental Standards in Europe

April 1, 2026 6:00 AM

Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry, is pleased to announce that, effective April 1, 2026, its fully owned subsidiary Eurisotop will serve as a direct supplier of CIL's Environmental Standards across Europe.Eurisotop, based in France, has been a member of the CIL group since 2001 and is widely recognized as a leading producer of deuterated NMR solvents and as a leading supplier of stable...

Read more

Notice Of Annual General Meeting In Vicore Pharma Holding AB (PUBL)

April 1, 2026 3:20 AM

The shareholders of Vicore Pharma Holding AB (publ)(STO:VICO), reg. no. 556680-3804 (the "Company"), are summoned to the Annual General Meeting on Wednesday 6 May 2026 at 15:00 CET at Baker McKenzie Advokatbyrå on Mäster Samuelsgatan 17, floor 6, SE-111 44 Stockholm, Sweden. Registration for the meeting will commence at 14:45 CET. Shareholders also have the opportunity to exercise their voting rights at the Annual General Meeting by voting in...

Read more

Next Gen Diagnostics Showcases Low-Cost, Automated WGS-Based Transmission Detection Service at SHEA Spring

April 1, 2026 12:00 AM

Next Gen Diagnostics (NGD) will showcase its new NGD System at SHEA Spring, in Chicago, April 7-10. Attendees can visit Booth #14 to see how NGD's end-to-end, on-premise service enables hospitals to detect and stop infection transmission in real time.The NGD System integrates complete robotic sample preparation, sequencing, bioinformatics and detection of the transmission of bacterial infection, all in a low hands-on-time, low cost workflow....

Read more

eXoZymes Provides Fourth Quarter and Full Year 2025 Update

March 31, 2026 4:20 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - provides an update on operations through the fiscal year ended December 31, 2025.Michael Heltzen, CEO of eXoZymes, states, "We've moved beyond our ‘big idea' potential and into execution - building differentiated assets and capabilities in a capital-efficient way that we believe...

Read more

BioInvent International AB Publishes Annual Report 2025

March 31, 2026 6:05 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2025 has been published. The Annual Report is attached to this press release in pdf format and is available on the company's website www.bioinvent.comBioInvent's key achievements in 2025 centered on...

Read more

Faron Pharmaceuticals Ltd: Director Dealing

March 31, 2026 2:15 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Tuomo Pätsi, Non-Executive Chairman of the Company, subscribed 400,002 ordinary shares in Faron at price of €0.5 per share on 30 March 2026, pursuant to the Rights Issue announced by the Company on 10 March 2026.Further details are set out in the Notification of Dealing Form below.For more...

Read more

MindMaze Therapeutics and Vibra Healthcare Announce Breakthrough RWE Results in High-Dose, High-Intensity Neurorehabilitation

March 31, 2026 1:34 AM

MindMaze Therapeutics (SIX:MMTX) and Vibra Healthcare today announced the results of a two-year multi-site quality improvement program demonstrating real-world evidence (RWE) that the integration of technology-enabled, high-dose therapy into standard inpatient rehabilitation significantly enhances functional recovery for stroke patients. These results were presented during the American Society of Neurorehabilitation (ASNR) annual conference.The...

Read more

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

March 30, 2026 9:00 AM

OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today announced that management will present at the upcoming Emerging Growth Conference. The presentation will provide investors and analysts with an updated overview of the Company's recent strategic milestones - including its VXM01 oncology asset and Woori IO's noninvasive glucose monitoring platform...

Read more

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

March 30, 2026 8:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced a strategic 12-part national media partnership with New to The Street, a leading financial media platform known for its integrated investor engagement and national television distribution. The collaboration is designed to enhance IGC Pharma's visibility across both...

Read more

uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies

March 30, 2026 7:00 AM

uBriGene Biosciences, a leading global CDMO specializing in lentiviral vector manufacturing and Advanced Therapy Medicinal Product (ATMP) development, today announced a strategic partnership with Cellinfinity BIO, a biotechnology company developing in vivoCAR-T therapies targeting hematologic and solid tumors.This strategic partnership will accelerate the clinical advancement of Cellinfinity BIO's therapeutic programs CIB-301 and CIB-350....

Read more

AI Maverick Intel Announces Letter of Intent to Acquire HEAL Access Canada Inc. as Initial Transaction Under Strategic ROFR Framework

March 30, 2026 7:00 AM

AI Maverick Intel, Inc. ("AIMV" or the "Company") today announced that it has entered into a non-binding letter of intent ("LOI") with HEAL Group Holdings Inc. ("HEAL") to acquire 100% of the issued and outstanding shares of HEAL Access Canada Inc. ("HAC"), a wholly owned subsidiary of HEAL.The proposed acquisition represents the first transaction undertaken by AIMV pursuant to the previously announced Right of First Refusal ("ROFR") Agreement...

Read more

Notice of Annual General Meeting in Alligator Bioscience AB

March 30, 2026 3:15 AM

The shareholders of Alligator Bioscience AB (STO:ATORX), Reg. No. 556597-8201, are invited to the annual general meeting to be held on Wednesday 6 May 2026, at 10.00 a.m CEST at Medicon Village, conference room Bengt, Scheelevägen 4 in Lund, Sweden.RIGHT TO PARTICIPATEShareholders that want to participate in the annual general meeting must be recorded in the company's share register kept by Euroclear Sweden AB as of Monday 27 April 2026 and,...

Read more